Table 1. Clinical characteristics of the CLL discovery cohort (n = 106).
| Factor | Subset | Number |
|---|---|---|
| Median Age | 66 years | |
| Range | 32 – 91 years | |
| Median Follow-up | 9.6 years | |
| Required treatment | Treated | 45 |
| Untreated | 61 | |
| Binet stage | A | 68 |
| B/C | 38 | |
| CD38 expression | <20% | 59 |
| ≥20% | 47 | |
| Genetics | 11q- / 17p- | 13 |
| N / O | 68 | |
| Not Determined | 25 | |
| IGHV Status | <98% | 76 |
| ≥98% | 28 | |
| Not Determined | 2 | |
| ZAP-70 expression | <20% | 59 |
| ≥20% | 47 |
11q- and 17p-: any FISH or karyotypic abnormality of 11q or 17p
N: No detectable cytogenetic aberration by fluorescence in situ hybridization (FISH)
O: Other cytogenetic abnormality (excluding 11q- or 17p-)
IGHV status: <98% sequence homology with the closest germline sequence (mutated); ≥98% sequence homology with the closest germline sequence (unmutated)